5 completed, 5 recruiting, 2 terminated, 1 withdrawn. 13 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 5, Recruiting 5, Terminated 2, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Lupus: new trials by email Literature Review of Lupus trials Research Report on Lupus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells - Lupus | Phase 1 | Recruiting | The Foundation for Orthopaedics and Regenerative Medicine | 15 | 2026-12-01 | 2026-10-20 |
| Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-11-18 | 2026-11-13 |
| CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus CART19 - SLE, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 24 | 2025-05-06 | 2026-09-24 |
| UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients Physical examination, Electrocardiogram, SF-36 questionnaire - SLE, Lupus | Phase 1 | Recruiting | LiveKidney.Bio | 10 | 2025-01-07 | 2025-09-11 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders Tafasitamab, Fludarabine phosphate, Cyclophosphamide - Autoimmune Disorders, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 47 | 2024-07-31 | 2026-11-03 |
| A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus BMS-986326, Placebo for BMS-986326 - Lupus | Phase 1 | Completed | Bristol-Myers Squibb | 45 | 2023-09-21 | 2026-05-26 |
| A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets BMS-986165-01, BMS-986165 Tablet, Famotidine - Lupus | Phase 1 | Completed | Bristol-Myers Squibb | 33 | 2019-08-22 | 2021-01-06 |
| A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients Methotrexate, Leucovorin, BMS-986165 - Lupus, Psoriatic Arthritis | Phase 1 | Completed | Bristol-Myers Squibb | 30 | 2018-01-08 | 2020-02-25 |
| Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus AMG 557, AMG 557 Placebo - Cutaneous Lupus, Lupus | Phase 1 | Terminated | Amgen | 1 | 2011-10-01 | 2014-01-10 |
| Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus AMG811, AMG811 Placebo - Cutaneous Lupus, Discoid Lupus | Phase 1 | Terminated | Amgen | 16 | 2010-08-01 | 2014-09-16 |
| A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus MEDI 545, Placebo - Lupus | Phase 1 | Completed | MedImmune LLC | 183 | 2007-06-01 | 2012-07-11 |
| Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE) MEDI-545, MEDI 545 - Lupus | Phase 1 | Completed | MedImmune LLC | 45 | 2006-03-01 | 2007-12-18 |
Lupus Erythematosus, Systemic (6) · Lupus Nephritis (3) · Autoimmune Diseases (2) · Lupus Erythematosus, Discoid (2) · Arthritis, Psoriatic (1) · Bronchiolitis Obliterans Syndrome (1) · Dermatitis, Atopic (1) · Graft vs Host Disease (1) · Lupus Erythematosus, Cutaneous (1) · Scleroderma, Systemic (1)
Skin and Connective Tissue Diseases (8) · Immune System Diseases (7) · Connective Tissue Diseases (6) · Skin Diseases (5) · Autoimmune Diseases (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Glomerulonephritis (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Nephritis (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Arthritis (1) · Bone Diseases (1)
deucravacitinib (2) · sifalimumab (2) · AMG 557 (1) · CTL019 chimeric antigen receptor (1) · Cyclophosphamide (1) · Electrocardiography (1) · Famotidine (1) · Leucovorin (1) · Methotrexate (1) · Physical Examination (1) · Pregnancy Tests (1) · Urinalysis (1) · baricitinib (1) · fludarabine phosphate (1) · tafasitamab (1)
Bristol-Myers Squibb (3) · Amgen (2) · MedImmune LLC (2) · Caribou Biosciences, Inc. (1) · Children's Hospital of Philadelphia (1) · LiveKidney.Bio (1) · M.D. Anderson Cancer Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · The Foundation for Orthopaedics and Regenerative Medicine (1)
United States (10) · Argentina (2) · Canada (2) · Netherlands (2) · Australia (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Germany (1) · Greece (1) · Poland (1) · Romania (1) · Spain (1) · United Kingdom (1)
Alexandra F Freeman, M.D. (1) · Barbara White, M.D. (1) · Caitlin Elgarten, MD (1) · Chadwick Prodromos, MD (1) · Chitra Hosing, MD (1) · Warren Greth, M.D. (1)
PMID 19479852, PMID 21798883, PMID 23400715, PMID 23754736, PMID 28118537, PMID 33687069
2017 (1)